Testing effectiveness (Phase 2)Study completedNCT03384654
What this trial is testing
Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Who this might be right for
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Janssen Research & Development, LLC 47